$Lexicon Pharmaceuticals(LXRX)$ Citi webcast takeaways: execution looks disciplined, with less emphasis on hype.

1. T1D NDA for Zynquista is targeted for a Q4 submission. Exton confirmed the Steno-1 exposure hurdle was hit in late August, saying the data is done and they're preparing it to get ready to submit. DKA rate came in lower than inTandem and similar to standard of care, which meets the risk-benefit criteria FDA has laid out.

2. HCM North Star is tracking toward Q1 '27. SONATA-HCM over-enrolled past 500 patients across 130+ sites, with a broad EF range and a unique background CMI cohort. Management framed a +3-pt placebo-adjusted KCCQ delta as a commercial home run.

3. Capital discipline on pain: Pilavapadin (LX9211) won't drain cash in a self-funded Phase 3. They're presenting new cardiometabolic preclinical data later this year to bundle into an expanded partnership package.

4. Genome 5000 plus AI: they're evaluating an AI query layer over 30 years of proprietary knockout data, which is the origin of Sota, LX9851, and LX9211, to explore untouched oncology and immuno areas. Pure optionality at this point.

$Novo-Nordisk A/S(NVO)$  $Viatris Inc.(VTRS)$  $ProShares Ultra Nasdaq Biotechnology(BIB)$  $SPDR S&P 500 ETF Trust(SPY)$